Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-17
2010-11-16
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S462000, C544S230000, C546S019000, C549S331000
Reexamination Certificate
active
07834026
ABSTRACT:
The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR12, NR1a, C(O) and O; E is selected from a bond, CR12, NR1a, C(O) and O; wherein at least one of A, B, D or E is CR12; and provided that when A is O, then E is not O; G is CR12; R is selected from NH2and OH; These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing termin differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
REFERENCES:
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5883102 (1999-03-01), Hamley et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 7544695 (2009-06-01), Berk et al.
patent: 2004/0142953 (2004-07-01), Delorme et al.
patent: 2005/0288282 (2005-12-01), Delorme et al.
patent: 2007/0117824 (2007-05-01), Berk et al.
patent: 1 378 510 (2004-01-01), None
patent: 1 541 574 (2005-06-01), None
patent: 11335375 (1999-12-01), None
patent: WO 01/30780 (2001-05-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 03/024448 (2003-03-01), None
patent: WO 03/076395 (2003-09-01), None
patent: WO 2003/075929 (2003-09-01), None
patent: WO 2003/076422 (2003-09-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/092686 (2003-11-01), None
patent: WO 2004/058234 (2004-07-01), None
patent: WO 2004/069823 (2004-08-01), None
patent: WO 2005/030704 (2005-04-01), None
patent: WO 2005/030705 (2005-04-01), None
patent: WO 2005/092899 (2005-10-01), None
Berk Scott C.
Close Joshua
Hamblett Christopher
Heidebrecht Richard W.
Kattar Solomon D.
Hui San-ming
Merck Sharp & Dohme Corp.
Muthard David A.
Su Li
Zarek Paul
LandOfFree
Spirocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spirocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186503